# **RSC Advances**



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available.

You can find more information about *Accepted Manuscripts* in the **Information for Authors**.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard <u>Terms & Conditions</u> and the <u>Ethical guidelines</u> still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.



www.rsc.org/advances

## Journal Name



## COMMUNICATION

# Biodegradable containers composed of anionic liposomes and cationic polypeptide vesicles

Received 00th January 20xx, Accepted 00th January 20xx

A. A. Yaroslavov,<sup>\*a</sup> O. V. Zaborova,<sup>a</sup> A. V. Sybachin,<sup>a</sup> I. V. Kalashnikova,<sup>a</sup> E. Kesselman,<sup>b</sup> J. Schmidt,<sup>b</sup> Y. Talmon,<sup>b</sup> A. R. Rodriguez<sup>c</sup> and T. J. Deming<sup>c,d</sup>

www.rsc.org/

Electrostatic complexation of liposomes, composed of anionic palmitoyloleoyl phosphatidyserine (POPS<sup>1-</sup>) and zwitterionic dioleoylphophatidylcholine (DOPC), with bilayer vesicles composed of cationic poly(L-lysine)-b-poly(L-leucine) block copolypeptides has been investigated. The complexation was characterized by several physicochemical methods with the following main conclusions: (a) All added liposomes are totally adsorbed on the polypeptide vesicles up to a certain saturation concentration. (b) The calculated number of liposomes per a single polypeptide vesicle is about 60. (c) The liposomes remain intact (i.e., do not leak) after being complexed with the vesicles. (d) Complexes are stable in physiological ionic strength solution with [NaCl] = 0.15 M. (e) The vesicles are effectively digested by proteolytic enzyme trypsin even when covered by liposomes. These findings as well as the high potential for loading of anionic liposomes and cationic vesicles with biologically active compounds make these multi-liposomal complexes promising in the drug delivery field.

#### Introduction

A bilayer lipid vesicle (liposome) represents a widely-used container for drug delivery.<sup>1,2</sup> The unique structure of liposomes allows encapsulation of both hydrophilic and hydrophobic compounds,<sup>3,4</sup> and liposomes with targeting moieties on their surfaces show preferable binding to target cells.<sup>1,3,5</sup> Vesicles have been described that release their contents in respond to external stimulus such as heat or light<sup>6</sup> or dissolved in water gases<sup>7</sup> as well as pH-sensitive liposomes that release entrapped drugs in more acidic areas, e.g. in cancer tumors.<sup>8</sup>

<sup>b.</sup> Department of Chemical Engineering, Technion-Israel Institute of Technology, 32000 Haifa, Israel

Concentration of liposomes within a rather small volume could lead to multi-liposomal containers capable of simultaneously carrying diverse drugs and therefore, lead to an increase of their therapeutic effect. Recently we have described electrostatic immobilization of anionic liposomes on the surface of polystyrene particles covered by grafted polycationic chains ("spherical polycationic brushes", SPB).<sup>9</sup> With this approach, several dozens of intact (undisrupted) liposomes with various contents could be concentrated within an approx. 350 nm sphere. However, the non-(bio)degradable polystyrene core strongly restricts the use of liposome/SPB conjugates for biomedical applications.

In the present communication, we describe for the first time a multi-liposomal container, prepared by complexation of multiple anionic liposomes with individual cationic polypeptide vesicle (CPV). These containers remained stable in a 0.15 M NaCl solution, but could eventually be destroyed in the presence of the proteolytic enzyme trypsin, which is well known to digest poly(L-lysine). The biodegradability of these complexes makes them promising as a multi-functional drug carriers.

#### Experimental

A poly(L-lysine)<sub>60</sub>-b-poly(L-leucine)<sub>20</sub> block copolypeptide,  $K_{60}L_{20}$ , (see ESI, Figure S1A) was synthesized using transition metal-mediated amino acid N-carboxyanhydride polymerization, which allows control over copolypeptide chain length and composition.<sup>10</sup> The Mw/Mn ratio determined using gel permeation chromatography/light scattering was found to be 1.13.<sup>11</sup>

In order to prepare the copolymer vesicles, we followed the procedure described elsewhere.<sup>11</sup> Briefly, the lyophilized copolymer was first swelled in THF and dispersed using a sonication bath, followed by addition of an equal volume of deionized water that yielded a slightly turbid suspension. The latter was exhaustively dialyzed against deionized water to remove the THF and then against a  $10^{-3}$  M TRIS buffer with pH = 7 that finally gave a suspension of cationic polypeptide

<sup>&</sup>lt;sup>a</sup> Department of Chemistry, M.V. Lomonosov Moscow State University, Leninskie Gory 1-3, 119991 Moscow, Russian Federation. E-mail: yaroslav@genebee.msu.su

<sup>&</sup>lt;sup>c</sup> Department of Bioengineering, University of California, Los Angeles, CA 90095 USA.

<sup>&</sup>lt;sup>d.</sup> Department of Chemistry and Biochemistry, University of California, Los Angeles, CA 90095 USA.

Electronic Supplementary Information (ESI) available: [details of any supplementary information available should be included here]. See DOI: 10.1039/x0xx00000x

#### COMMUNICATION

Journal Name

vesicles (CPVs) (see their structure in ESI, Figure S1B). The dynamic light scattering (DLS) study of the vesicle suspension with a Brookhaven Zeta Plus showed two populations with the main contribution of particles with diameter of 200 nm (see ESI, Figure S2).

#### **Results & discussion**

The number (concentration) of cationic groups in CPVs, exposed into the surrounding water solution and available for electrostatic coupling with anionic liposomes, was estimated via electrophoretic titration of a CPV suspension in a pH = 7TRIS buffer by a solution of sodium poly(styrene sulfonate) (NaPSS) in a pH = 7 TRIS buffer with use of a Brookhaven Zeta Plus. As shown earlier,<sup>12</sup> a degree of protonation of poly(Llysine) amino groups at pH = 7 is close to maximum (100%). The interaction of two oppositely charged polyions, positive protonated poly(L-lysine) ions and negative poly(styrene sulfonate) anions, was accompanied by mutual neutralization of their charges and corresponding change in the electrophoretic mobility (EPM) of the resulting complex particles. Complete neutralization of CPV cationic charges by NaPSS anionic charges (i.e. the EPM=0 point) was achieved at a concentration of sulfonate subunits [Sulfo-] =  $7 \times 10^{-3}$  M that is equal to the effective concentration of cationic L-lysine on the outer CPV side, [Lys+]<sub>outer</sub>. According to the assumed unilamellar structure of the copolypeptide vesicles<sup>11</sup> (see also ESI, Figure S1B), poly-L-lysine chains are nearly uniformly (fiftyfifty) exposed into the surrounding solution and inside water cavity of vesicles. From there, a total lysine concentration in the CPV sample, titrated by NaPSS, turns to be [Lys+] =  $2 \times [Lys+]_{outer} = 1.4 \times 10^{-2} M.$ 

In a typical experiment, a pH = 7 buffer solution of CPV with  $[Lys+]_{outer} = 10^{-4}$  M was mixed with a varying amount of aqueous suspension of unilamellar liposomes (ca. 40-50 nm in diameter) prepared by sonication (see synthetic procedure in ESI. S1) and composed of а zwitterionic dioleoylphophatidylcholine (DOPC) and an anionic palmitoyloleoyl phosphatidyserine (POPS<sup>1-</sup>) (see chemical structures of lipids in ESI, Figure S3A and Figure S3B). The molar fraction of anionic lipid  $v = [POPS^{1-}]/([POPS^{1-}] + [DOPC])$ in the liposomes was equal to 0.1. Interaction of DOPC/POPS<sup>1</sup> liposomes with the CPVs altered the surface charge of vesicles, which was monitored using a Brookhaven Zeta Plus (Figure 1). Adsorbed liposomes caused the EPM of liposome/CPV complex particles to decrease down to zero at 0.89 mg/mL liposome concentration or  $[POPS^{1-}]_{EPM=0} = 1.13 \times 10^{-4}$  M. At higher liposome concentrations, the charge of particles became negative due to adsorption of an excess of liposomes over the amount needed for complete neutralization of the vesicle charge.





A key question concerns the integrity of adsorbed liposomes that relates to the quality of immobilized liposomal containers. In order to study complexed liposome integrity, a suspension of DOPC/POPS<sup>1-</sup> liposomes filled with a 1 M NaCl solution was prepared. Formation of defects in the liposomal membrane should lead to leakage of salt from the liposomes into the surrounding solution, thus increasing suspension conductivity. Initially, a control experiment was carried out in which a NaClloaded liposome suspension was treated with a Triton X-100 solution that resulted in disruption of liposomes as expected, and resulted in NaCl leakage and a subsequent rise in the conductivity detected by a CDM 83 Radiometer conductometer. A NaCl-loaded liposome suspension was next mixed with a suspension of the CPVs that resulted in only a negligible increase in the conductivity. We concluded from there that the anionic DOPC/POPS<sup>1-</sup> liposomes maintain their integrity after adsorption on the surface of cationic polypeptide vesicles.

Liposome adsorption on CPVs was quantified using the earlier described procedure.<sup>9</sup> A series of mixtures was prepared with a constant CPV concentration (0.05 mg/mL or [Lys+]<sub>outer</sub> =  $1 \times 10^{-4}$  M) and varying concentrations of DOPC/POPS<sup>1-</sup> liposomes with 0.05 wt% of 1,2-dioleoyl-sn-glycero-3phosphoethanolamine-N-(1-pyrenesulfonyl) (pyrene-PE), (see chemical structure in ESI, Figure S3C), a fluorescent lipid incorporated into the bilayer during the liposome preparation. After 30 minutes the mixtures were centrifuged at 18,000 rpm for 40 min using a J2-21 Beckman micro centrifuge, the fluorescent intensities in the clear supernatants were measured. No fluorescence, i.e. no liposome, was detected in the supernatants up to 0.98 mg/mL lipid concentration or  $[POPS^{1-}]_{max} = 1.24 \times 10^{-4}$  M, which reflected complete liposome binding to the CPVs within the indicated lipid interval (see ESI. Figure S4).

Journal Name

#### ease do not adjust margins RSC Advances

#### COMMUNICATION



**Fig. 2.** Cryo-TEM images of (A) CPV suspension, (B) a 1 mg/mL DOPC/POPS<sup>1-</sup> liposome suspension, (C) and liposomes/CPV complexes. CVP concentration 0.025 mg/mL;  $[Lys+]_{outer} = 5 \times 10^{-5}$  M; liposomes concentration 1 mg/ml;  $10^{-3}$  M TRIS buffer, pH = 7; white bar 100 nm

The above electro-3oretic, conductivity and fluorescence data allows a deeper insight into the structure and composition of the liposome/CPV complex. As shown in Figure 1, the liposome/CPV complex became electroneutral (with EPM=0) at a concentration of adsorbed liposomes of 0.89 mg/mL or a total concentration of POPS<sup>1-</sup> from both liposome leaflet  $[POPS^{1-}] = 1.13 \times 10^{-4}$  M. The latter was equal to a concentration of L-lysine subunits on the outer side of vesicles [Lys+]<sub>outer</sub> = 1×10<sup>-4</sup> M. Taking into account a uniform (fifty-fifty) distribution of POPS<sup>1-</sup> molecules between both leaflets in the membrane of the initial DOPC/POPS<sup>1-</sup> liposomes<sup>13</sup> and preservation of the liposome integrity after adsorption, the above mentioned equality of the two concentrations, [POPS<sup>1-</sup>] and [Lys+]<sub>outer</sub>, at EPM=0 can only be interpret in terms of the CPV-induced migration of POPS<sup>1-</sup> molecules from the inner to outer membrane leaflet (flip-flop). Simultaneously, an equivalent amount of zwitterionic (neutral) DOPC molecules move in the opposite direction: from the inner to outer leaflet, which allows the adsorbed liposomes to retain their integrity. Earlier, we have described complexation of anionic liposomes with polystyrene microspheres grafted by polycationic chains, "spherical polycationic brushes".<sup>14</sup> We measured binding of intact (undisrupted) liposomes and the anionic lipid flip-flop in the bound liposomes. We see now that complexation of anionic liposomes with the CPVs occurs by a similar process. In both cases, a hydrophilic layer of grafted macromolecules prevents a direct contact of immobilized liposomes with the solid polystyrene and poly-L-leucine core and thereby ensures the integrity of immobilized liposomes.

Additional information about the morphology of the liposome/CPV complex was obtained by cryogenic transmission electron microscopy (cryo-TEM). **Figure 2A** shows a cryo-TEM micrograph of the polypeptide vesicle. A dark ring in the figure reflects the hydrophobic polyleucine layer of the vesicular membrane. Polylysine chains projecting from the polyleucine layer are not visible in the figure since no contrast-enhancing material was used. A cryo-TEM of the DOPC/POPS<sup>1-</sup> liposomes by themselves (**Figure 2B**) gives sizes in agreement with the DLS measurements. **Figure 2C** is a cryo-TEM micrograph of liposome/CPV complexes in which

CPVs (bigger rings) are covered by multiple liposomes (smaller rings). Clearly, both CPVs and liposomes retain their normal spherical shape (do not disrupt) upon complexation.

The capacity of CPV towards anionic liposomes, i.e. the maximum number of liposomes capable of complexing with a single CPV (N), can be estimated comparing the surface area of a single cationic vesicle  $S_{CPV} = \pi (200)^2 \text{ nm}^2$  and the surface area occupied by an adsorbed liposome  $S_{ad\_lip} = \pi (25)^2 \text{ nm}^2$ . Calculation gives N = SµG /  $S_{ad\_lip} \approx 60$  liposomes with mean diameter 50 nm per a cationic vesicle.

Another question of great importance concerns the stability of liposome/CPV complexes in aqueous salt media. When possible biomedical applications of the liposome/CPV complexes are considered, a special interest is paid to their stability in physiological ionic strength solution with [NaCl]=0.15 M. We have investigated this question using a fluorescence technique. Cationic polymers are known to be effective fluorescence quenchers due to collisional quenching.<sup>15</sup> We detected formation and dissociation of liposome/CPV complexes by measuring the fluorescence intensity of a rhodamine-labeled lipid, 1,2-dimyristoyl-snglycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rh-PE) (see chemical structure in ESI, Figure S3D), incorporated into the liposomal membrane. Addition of an aqueous CPV suspension to a suspension of rhodamine-labeled liposomes led to a decrease in the fluorescence intensity (Figure 3A). Further addition of a NaCl solution to the complex suspension had no effect on the fluorescence intensity up to [NaCl]=0.3 M (Figure 3B). Preservation of the liposome/CPV complexes in physiological solution was thus confirmed.

Biodegradability is a key requirement for carriers of biologically active substances. Liposomes are known to decompose when attacked by lipase, a common enzyme hydrolyzing ester bonds in lipid molecules and involving in diverse biological processes.<sup>16,17</sup> Biodegradability of the polypeptide core was shown in model experiments where decomposition of the positive complex particles (prepared in an excess of CPVs) was initiated by addition of the proteolytic enzyme trypsin, capable of cleaving amide bonds in the



**Fig. 3.** (A) Fluorescence intensity of pyrene-labeled v = 0.1 DOPC/POPS<sup>1.</sup> liposomes vs. CPV concentration. [POPS<sup>1.</sup>] =  $1.4 \times 10^{-4}$ . (B) Fluorescence intensity of rhodamine-labeled liposomes complexed with CPV vs. NaCl concentration. Copolymer concentration 0.052 mg/mL; [Lys+]<sub>outer</sub> =  $1.4 \times 10^{-4}$  M; [POPS<sup>1.</sup>] =  $1.4 \times 10^{-4}$ .  $10^{-3}$  M TRIS buffer, pH = 7.

polypeptide copolymer. The proteolysis was monitored by DLS measurement of particle size in the suspension (Figure 4A). Initially, only a slight change in the particle size was found in the absence of trypsin (curve 1). Injection of trypsin (curve 2) had a negligible effect on the particle size within first 1 hour. Then the particle size began to increase. Approx. 1 hour later, large aggregates were detected in the system, which finally disintegrated down to 50 nm particles. In parallel, the EPM of complex particles was monitored (Figure 4B) with a negligible change of particle EPM in the absence of trypsin (curve 1') and a significant change of their EPM after addition of trypsin (curve 2'). In the latter case,

the EPM eventually decreased down to zero and then became negative 2 hours after trypsin addition.

Based on electrophoteric and light scattering data, the following metamorphosis of the liposome/CPV complex can be proposed (**Figure 5**). In the absence of trypsin, only slight changes in the particle size and their EPM are detected showing the stability of polypeptide blocks and the vesicular structure of complex particles (I). Addition of enzyme induces the cleavage of amide bonds in poly(L-lysine) chains thus decreasing a relative positive charge of the complex particles (II). In the beginning of the enzymatic reaction, the total charge of complex particles is high enough in order to suppress particle aggregation (II). The latter becomes appreciable when EPM of complex particles approaches zero; partially destroyed



**Fig. 4.** Time-dependent changes in size (A) and EPM (B) of liposome/CPV complex in the presence (curves 1 and 1') and in the absence of trypsin (curves 2 and 2'). v=0.1 DOPC/POPS<sup>1.</sup> liposome concentration 1.76 mg/mL; copolymer concentration 0.3 mg/mL ([Lys+]<sub>outer</sub> =  $6 \times 10^{-4}$  M); trypsin concentration 0.032 mg/mL;  $10^{-2}$  M TRIS buffer, pH = 7.9.

CPVs can be also involved in the aggregates (III). Finally, the unilamellar structure of CPV is completely destroyed and only free anionic liposomes are found in the suspension (IV) and the remaining hydrophobic poly leucine fragments precipitated. In



**Fig. 5.** Trypsin-induced metamorphosis of liposome/CPV complex (schematical presentation). Complex before addition of trypsin (I), initial stage of complex reorganization (II), aggregates of electroneutral complex particles (III), particles after disruption of polypeptide vesicles (IV).

Journal Name

biological environment, liposomes will be hydrolyzed by diverse lipases down to smaller species thus ensuring biodegradability of the entire liposome/CPV complex particle.

#### Conclusions

Journal Name

We have shown for the first time electrostatic complexation of anionic liposomes with cationic unilamellar vesicles whose membranes consist of a poly(L-lysine)-b-poly(L-leucine) block copolypeptides. The liposomes were found to retain their integrity after complexation. A single 200 nm copolypeptide vesicle binds several dozens of 50 nm liposomes; the resulting multi-liposomal complex remains stable (does not dissociate to same time, the complex disintegrates when digested by the proteolytic enzyme trypsin. Facile preparation, stability in physiological solution, biodegradability and the high

potential for loading of anionic liposomes and cationic vesicles with biologically active compounds make these multiliposomal complexes promising in the drug delivery field.

#### Acknowledgements

This work was in part supported by the Russian Science Foundation (Project 14-13-00255)

#### References

- 1 V. P. Torchilin, Nat. Rev. Drug Discovery, 2005, 4, 145.
- 2 T. M. Allen and P. R. Cullis, *Adv. Drug Deliv. Rev.*, 2014, **65**, 36; G. Gregoriadis and A. T. Florence, *Drugs*, 1993, **45(1)**, 15.
- S. Clerc and Y. Barenholz, *Biochim. Biophys. Acta*, 1995, 1240(2), 257; Y. Yao, M Xue, Z. Zhang, M. Zhang, Y. Wang and F. Huang*Chem. Sci.*, 2013,4, 3667
- 4 V. Weissig, *Liposomes: Methods and Protocols, Vol. 1: Pharmaceutical Nanocarriers*, Humana Press, Springer, New York, 2010, p. 559; V. Joguparthi, T.-X. Xiang and B. D. Anderson, *J. Pharm. Sci.*, 2008, **97(1)**, 400.
- 5 F. Perche and V. P. Torchilin, *J. Drug Deliv.*, 2013, **2013**, 705265.
- 6 B. M. Dicheva, T. L. M. ten Hagen, L. Li, D. Schipper, A. L. B. Seynhaeve, G. C. van Rhoon, A. M. M. Eggermont, L. H. Lindner and G. A. Koning, *Nano Lett.*, 2013, **13(6)**, 2324; A. Pashkovskaya, E. Kotova, Y. Zorlu, F. Dumoulin, V. Ahsen, I. Agapov and Yu. Antonenko, *Langmuir*, 2010, **26(8)**, 5726; A. Puri, *Pharmaceutics*, 2014, **6**, 1.
- 7 K. Jie, Y. Zhou, Y. Yao, B. Shi, and F. Huang, J. Am. Chem. Soc., 2015, **137**, 10472.
- O. Warburg, K. Posener and E. Negelein, *Biochem. Z.*, 1924, 152, 319; G. Helmlinger, A. Sckell, M. Dellian, N. S. Forbes and R. K. Jain, *Clin. Cancer Res.*, 2002, 8(4), 1284.
- 9 A. V. Sybachin, O. V. Zaborova, M. Ballauff, E. Kesselman, J. Schmidt, Y. Talmon, F. M. Menger and A. A. Yaroslavov, *Langmuir*, 2012, **28(46)**, 16108.
- 10 T. J. Deming, *Nature*, 1997, **390**, 386; J. Deming, *J. Polym. Sci. Polym. Chem. Ed.*, 2000, **38**, 3011.
- 11 E. P. Holowka, D. J. Pochan and T. J. Deming, J. Am. Chem. Soc., 2005, **127**, 12423.
- 12 A. A. Yaroslavov, O. Ye. Kuchenkova, I. B. Okuneva, N. S. Melik-Nubarov, N. O. Kozlova, V. I. Lobyshev, F. M. Menger and V. A. Kabanov, *Biochim. Biophys. Acta, Biomembr.*, 2003, 1611(1–2), 44.

- A. A. Yaroslavov, A. V. Sybachin, O. V. Zaborova, V.N. Orlov, M. Ballauff, Y. Talmon and F.M. Menger, *Chem.-Eur. J.*, 2013, 1(41), 13674.
- 14 A. V. Sybachin, O. V. Zaborova, V. N. Orlov, P. I. Semenyuk, M. Ballauff, E. Kesselman, J. Schmidt, Y. Talmon, F. M. Menger and A.A. Yaroslavov, *Langmuir*, 2014, **30(9)**, 2441.
- 15 J. R. Lakowicz, *Principles of Fluorescence Spectroscopy*, 3rd ed., Springer, New York, 2006, p. 278.
- 16 M. Kokkona, P. Kallinteri, D. Fatouros and S. G. Antimisiaris, *Eur. J. Pharm. Sci.*, 2000, **9(3)**, 245.
- 17 G. Bozzuto, A. Molinari, Int. J. Nanomedicine, 2015, 10, 975

